Business Context and Reporting Period
This Form 8-K is filed by Point Capital, Inc. (not Silo Pharma, Inc.) on February 10, 2016. The report addresses corporate governance changes regarding the compensation of independent directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports specific cash compensation payments to directors:
- Van E. Parker: $30,000 for previous services.
- Joel Stone: $20,000 for previous services.
- Leonard Schiller: $20,000 for previous services.
- Future Compensation: $2,500 per quarter per director for routine services starting in calendar year 2016.
Material Changes
Effective February 10, 2016, the Board of Directors cancelled stock options previously granted to three independent directors (Van E. Parker, Joel Stone, and Leonard Schiller). None of the vested options had been exercised. These options were replaced with cash compensation arrangements.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The primary unusual item is the conversion of equity-based compensation (options) to cash for independent directors.
Investor Verification Checklist
- Verify the registrant name is Point Capital, Inc., not Silo Pharma, Inc.
- Confirm the total cash outflow of $70,000 for past services and the ongoing quarterly liability of $7,500 ($2,500 x 3 directors).
- Review the impact of cancelling unexercised options on the company's capital structure and dilution.